PLSE
Pulse Biosciences, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Buy
+39/100
Last price
48.96
▼ 0.79 (1.59%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
49.11
Prev close
49.75
Day high
49.93
Day low
48.13
Volume
157.17K
Market cap
$3.49B
P/E (TTM)
—
52W range
12.56 – 58.90
Day trading desk
Gap from prior close
-1.29%
Prior close 49.75
VWAP
48.78
+0.36% from price
Relative volume
0.30×
Quiet session
Session range
3.74%
48.13 – 49.93
Position in range
46%
Mid range
ATR (14D)
2.88
5.87% of price
Prior day high
51.26
PDH
Prior day low
48.62
PDL
Bid / ask spread
—
Quote not published
Session volume
153.47K
Avg 503.56K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.92%
-3.9%
1M
+0.35%
-1.2%
3M
+79.74%
+76.3%
6M
+156.87%
+141.9%
YTD
+256.59%
+242.6%
1Y
+151.72%
+136.0%
3Y
+1,107.40%
+1,025.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PLSE open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
50.67M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 11, 26 | LAVIOLETTE PAUL A Chief Executive Officer |
BUY | 15.00K | $295.35K | Direct |
| May 11, 26 | DUGGAN ROBERT WILLIAM Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 660.23K | $13.00M | Direct |
| May 11, 26 | DUGGAN ROBERT WILLIAM Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 660.23K | $13.00M | Direct |
| Feb 18, 26 | DANAHY KEVIN PATRICK Officer |
CONVERSION | 5.00K | $7.65K | Direct |
| Feb 18, 26 | DANAHY KEVIN PATRICK Officer |
SELL | 5.00K | $118.20K | Direct |
| Feb 17, 26 | DANAHY KEVIN PATRICK Officer |
CONVERSION | 60.00K | $91.80K | Direct |
| Feb 17, 26 | DANAHY KEVIN PATRICK Officer |
SELL | 60.00K | $1.41M | Direct |
| Feb 11, 26 | DANAHY KEVIN PATRICK Officer |
CONVERSION | 60.00K | $91.80K | Direct |
| Feb 11, 26 | DANAHY KEVIN PATRICK Officer |
SELL | 60.00K | $1.40M | Direct |
| Oct 2, 25 | DANAHY KEVIN PATRICK Officer |
CONVERSION | 4.60K | $7.04K | Direct |
| Oct 2, 25 | DANAHY KEVIN PATRICK Officer |
SELL | 4.60K | $85.24K | Direct |
| Sep 19, 25 | DANAHY KEVIN PATRICK Officer |
CONVERSION | 20.40K | $31.21K | Direct |
| Sep 19, 25 | DANAHY KEVIN PATRICK Officer |
SELL | 20.40K | $377.19K | Direct |
| Sep 17, 25 | UECKER DARRIN R Chief Technology Officer |
CONVERSION | 206.53K | $826.14K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BARRETT BURKE T |
Former | 63.17K | Sale |
DANAHY KEVIN PATRICK |
Officer | 43.30K | Conversion of Exercise of derivative security |
DUGGAN ROBERT WILLIAM |
Director and Beneficial Owner of more than 10% of a Class of Security | 49.29M | Purchase |
LAVIOLETTE PAUL A |
Chief Executive Officer | 15.85K | Purchase |
UECKER DARRIN R |
Chief Technology Officer | 284.41K | Conversion of Exercise of derivative security |
ZANGANEH MAHKAM |
Director | 873.47K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$3.49B
Enterprise value$3.45B
Revenue (TTM)$1.19M
Gross profit$3.00K
EBITDA$-82.62M
Net income$-80.06M
EPS (TTM)$-1.18
Free cash flow$-34.29M
Total cash$101.62M
Total debt$6.77M
Book value / share$1.41
Shares outstanding71.32M
Float20.65M
Short % of float14.72%
Dividend yield0.00%
Beta (5Y)1.57
Valuation & profitability ratios
Trailing P/E—
Forward P/E-41.85
PEG ratio—
Price / sales—
Price / book34.85
EV / revenue2,914.31
EV / EBITDA-41.80
Gross margin0.25%
Operating margin-5823.04%
Profit margin0.00%
Return on equity-78.49%
Return on assets-44.34%
Debt / equity6.81
Current ratio9.63
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $350.00K | $0 | $0 | $700.00K | — | — |
| Operating revenue | $350.00K | $0 | $0 | $700.00K | — | — |
| Cost of revenue | $539.00K | $0 | $0 | $11.94M | — | — |
| Gross profit | -$189.00K | $0 | $0 | -$11.24M | — | — |
| Research & development | $44.72M | $32.34M | $27.80M | $20.84M | — | +38.3% |
| Selling, general & admin | $32.03M | $23.92M | $15.78M | $25.97M | — | +33.9% |
| Total operating expense | $76.75M | $56.26M | $43.57M | $46.81M | — | +36.4% |
| Operating income | -$76.94M | -$56.26M | -$43.57M | -$58.06M | — | -36.8% |
| Net interest income | $4.21M | $2.69M | $1.36M | -$448.00K | — | +56.5% |
| Pre-tax income | -$72.78M | -$53.59M | -$42.21M | -$58.51M | — | -35.8% |
| Tax provision | — | $0 | $0 | $0 | $0 | — |
| Net income | -$72.78M | -$53.59M | -$42.21M | -$58.51M | — | -35.8% |
| Net income to common | -$72.78M | -$53.59M | -$42.21M | -$58.51M | — | -35.8% |
| Basic EPS | -1.08 | -0.92 | -0.85 | -1.69 | — | -17.4% |
| Diluted EPS | -1.08 | -0.92 | -0.85 | -1.69 | — | -17.4% |
| EBIT | -$76.94M | -$56.26M | -$43.57M | -$58.06M | — | -36.8% |
| EBITDA | -$75.87M | -$55.08M | -$42.37M | -$56.70M | — | -37.7% |
| Basic shares | 67.40M | 58.40M | 49.74M | 34.51M | — | +15.4% |
| Diluted shares | 67.40M | 58.40M | 49.74M | 34.51M | — | +15.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $80.73M | $118.04M | $44.37M | $61.14M | — | -31.6% |
| Cash & short-term investments | $80.73M | $118.04M | $44.37M | $61.14M | — | -31.6% |
| Accounts receivable | $274.00K | $0 | — | $0 | $61.00K | — |
| Inventory | $136.00K | $0 | — | $0 | $5.82M | — |
| Total current assets | $83.42M | $119.45M | $45.33M | $62.15M | — | -30.2% |
| Property, plant & equipment | $7.06M | $8.32M | $8.78M | $10.02M | — | -15.2% |
| Goodwill & intangibles | $3.37M | $4.01M | $4.68M | $5.34M | — | -16.1% |
| Total assets | $94.54M | $132.46M | $59.15M | $77.88M | — | -28.6% |
| Total current liabilities | $7.92M | $10.05M | $6.71M | $5.98M | — | -21.2% |
| Current debt | — | — | — | $917.00K | $436.00K | — |
| Long-term debt | — | — | — | $65.00M | — | — |
| Total debt | $7.53M | $8.90M | $9.14M | $75.96M | — | -15.4% |
| Total liabilities | $13.88M | $17.60M | $14.79M | $80.13M | — | -21.1% |
| Retained earnings | -$463.28M | -$390.50M | -$336.92M | -$294.70M | — | -18.6% |
| Shareholder equity | $80.66M | $114.86M | $44.36M | -$2.25M | — | -29.8% |
| Working capital | $75.50M | $109.39M | $38.62M | $56.17M | — | -31.0% |
| Net tangible assets | $77.29M | $110.85M | $39.68M | -$7.59M | — | -30.3% |
| Shares issued | 67.84M | 65.93M | 56.08M | 37.87M | — | +2.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$72.78M | -$53.59M | -$42.21M | -$58.51M | -35.8% |
| Depreciation & amortisation | $1.07M | $1.18M | $1.21M | $1.35M | -9.1% |
| Stock-based compensation | $21.46M | $13.59M | $7.18M | $5.19M | +57.9% |
| Change in working capital | -$5.02M | $1.55M | $768.00K | -$3.72M | -424.2% |
| Operating cash flow | -$54.12M | -$36.34M | -$33.04M | -$47.01M | -48.9% |
| Capital expenditure | -$335.00K | -$125.00K | -$121.00K | -$401.00K | -168.0% |
| Investing cash flow | -$335.00K | -$125.00K | -$121.00K | -$401.00K | -168.0% |
| Financing cash flow | $17.15M | $110.14M | $16.39M | $79.94M | -84.4% |
| Free cash flow | -$54.46M | -$36.47M | -$33.16M | -$47.41M | -49.3% |
| End cash position | $80.73M | $118.04M | $44.37M | $61.14M | -31.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $434.00K | $401.00K | $264.00K | $86.00K | $0 | — | +8.2% |
| Operating revenue | $434.00K | $401.00K | $264.00K | $86.00K | $0 | — | +8.2% |
| Cost of revenue | $273.00K | $370.00K | $260.00K | $279.00K | $0 | — | -26.2% |
| Gross profit | $161.00K | $31.00K | $4.00K | -$193.00K | $0 | — | +419.4% |
| Research & development | $16.98M | $12.59M | $10.93M | $11.39M | $12.09M | — | +34.8% |
| Selling, general & admin | $8.46M | $6.59M | $7.33M | $8.78M | $8.19M | — | +28.3% |
| Total operating expense | $25.43M | $19.18M | $18.26M | $20.17M | $20.27M | — | +32.6% |
| Operating income | -$25.27M | -$19.15M | -$18.25M | -$20.37M | -$20.27M | — | -32.0% |
| Net interest income | $600.00K | $593.00K | $825.00K | $1.00M | $1.13M | — | +1.2% |
| Pre-tax income | -$24.66M | -$18.58M | -$17.43M | -$19.39M | -$19.17M | — | -32.7% |
| Tax provision | — | — | — | — | $0 | $0 | — |
| Net income | -$24.66M | -$18.58M | -$17.43M | -$19.39M | -$19.17M | — | -32.7% |
| Net income to common | -$24.66M | -$18.58M | -$17.43M | -$19.39M | -$19.17M | — | -32.7% |
| Basic EPS | -0.36 | -0.27 | -0.26 | -0.29 | -0.28 | — | -33.3% |
| Diluted EPS | -0.36 | -0.27 | -0.26 | -0.29 | -0.28 | — | -33.3% |
| EBIT | -$25.27M | -$19.15M | -$18.25M | -$20.37M | -$20.27M | — | -32.0% |
| EBITDA | -$25.02M | -$18.89M | -$17.99M | -$20.11M | -$20.00M | — | -32.4% |
| Basic shares | 69.20M | 67.99M | 67.79M | 67.39M | 67.28M | — | +1.8% |
| Diluted shares | 69.20M | 67.99M | 67.79M | 67.39M | 67.28M | — | +1.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $101.62M | $68.32M | $80.73M | $95.21M | $106.35M | +48.7% |
| Cash & short-term investments | $101.62M | $68.32M | $80.73M | $95.21M | $106.35M | +48.7% |
| Accounts receivable | $122.00K | $157.00K | $274.00K | $15.00K | — | -22.3% |
| Inventory | $236.00K | $206.00K | $136.00K | $57.00K | $51.00K | +14.6% |
| Total current assets | $105.70M | $71.13M | $83.42M | $97.16M | $108.16M | +48.6% |
| Property, plant & equipment | $6.45M | $6.72M | $7.06M | $7.37M | $7.72M | -4.0% |
| Goodwill & intangibles | $3.01M | $3.20M | $3.37M | $3.53M | $3.70M | -5.8% |
| Total assets | $115.56M | $81.62M | $94.54M | $108.77M | $120.25M | +41.6% |
| Total current liabilities | $10.98M | $9.80M | $7.92M | $9.70M | $8.98M | +12.1% |
| Total debt | $6.77M | $7.16M | $7.53M | $7.89M | $8.24M | -5.4% |
| Total liabilities | $16.06M | $15.32M | $13.88M | $16.07M | $15.76M | +4.8% |
| Retained earnings | -$506.52M | -$481.86M | -$463.28M | -$445.85M | -$426.46M | -5.1% |
| Shareholder equity | $99.50M | $66.30M | $80.66M | $92.69M | $104.49M | +50.1% |
| Working capital | $94.72M | $61.33M | $75.50M | $87.46M | $99.18M | +54.4% |
| Net tangible assets | $96.49M | $63.10M | $77.29M | $89.16M | $100.79M | +52.9% |
| Shares issued | 70.80M | 68.23M | 67.84M | 67.74M | 67.28M | +3.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$24.66M | -$18.58M | -$17.43M | -$19.39M | -$19.17M | -32.7% |
| Depreciation & amortisation | $254.00K | $255.00K | $259.00K | $256.00K | $273.00K | -0.4% |
| Stock-based compensation | $4.97M | $1.91M | $4.97M | $5.62M | $5.19M | +160.1% |
| Change in working capital | $392.00K | $1.17M | -$2.86M | $182.00K | $617.00K | -66.4% |
| Operating cash flow | -$18.71M | -$14.60M | -$14.76M | -$13.04M | -$12.81M | -28.2% |
| Capital expenditure | -$90.00K | -$33.00K | -$105.00K | -$62.00K | -$123.00K | -172.7% |
| Investing cash flow | -$90.00K | -$33.00K | -$105.00K | -$62.00K | -$123.00K | -172.7% |
| Financing cash flow | $52.10M | $2.21M | $381.00K | $1.97M | $0 | +2,255.3% |
| Free cash flow | -$18.80M | -$14.63M | -$14.86M | -$13.10M | -$12.93M | -28.5% |
| End cash position | $101.62M | $68.32M | $80.73M | $95.21M | $106.35M | +48.7% |
Options analytics
Put / call volume
0.16
Call-heavy session
Put / call open interest
0.13
Positioning, not flow
Max pain
22.00
-55.1% from spot
ATM implied vol
63.7%
Nearest strike to spot
Skew (10% OTM)
+67.1%
Puts bid over calls
Call volume
204
Contracts, this expiry
Put volume
33
Contracts, this expiry
Heaviest call OI
60.00
144 contracts
Heaviest put OI
45.00
24 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.29 | -0.28 | +1.5% |
| Mar 2026 | -0.22 | -0.24 | -9.7% |
| Dec 2025 | -0.21 | -0.18 | +14.3% |
| Sep 2025 | -0.31 | -0.29 | +6.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.29 | 4 | $526.00K | +511.6% |
| Next quarter | -0.30 | 4 | $684.00K | +159.1% |
| Current year | -1.11 | 4 | $2.02M | +477.7% |
| Next year | -1.17 | 4 | $6.73M | +233.0% |
Analyst targets & ownership
Mean target$56.50
High target$73.00
Low target$35.00
Implied upside15.40%
Analyst count6
ConsensusSTRONG BUY
Strong buy / Buy1 / 5
Hold0
Sell / Strong sell0 / 0
Held by insiders71.05%
Held by institutions15.42%
Institutions holding169
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
50.35
-2.77% from price
SMA 20
51.63
-5.17% from price
SMA 50
47.91
+2.20% from price
SMA 100
37.45
+30.72% from price
SMA 200
28.26
+73.26% from price
EMA 12
50.36
-2.79% from price
EMA 26
50.05
-2.17% from price
EMA 50
46.74
+4.74% from price
RSI (14)
47.1
Neutral
MACD (12,26,9)
0.32
Hist -0.74
ATR (14)
2.88
5.87% of price
Realised vol 30D
62.4%
Annualised
Bollinger upper
55.54
20, 2σ
Bollinger lower
47.71
20, 2σ
50 / 200 cross
Golden
47.91 vs 28.26
Trend bias
Above 200
+73.26%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.03
More volatile than market
Correlation to SPY
0.30
Loosely linked
Realised vol 30D
62.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-36.5%
Peak to trough
Max drawdown 5Y
-95.0%
Peak to trough
ATR 14
2.88
5.87% of price
Beta (reported)
1.57
5Y monthly, from filing
Short interest
Shares short
3.14M
Prior 2.77M
Change vs prior
+13.5%
Shorts adding
% of float
14.72%
Elevated
% of shares out
4.40%
Against total outstanding
Days to cover
5.2
Crowded exit
Float
20.65M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Sep 23, 26 | BTIG | INITIATED | — | Buy |
| Sep 9, 26 | Freedom Capital Markets | INITIATED | — | Buy |
| Aug 17, 26 | Needham | INITIATED | — | Buy |
| Aug 10, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jun 4, 26 | Canaccord Genuity | INITIATED | — | Buy |
| Jul 7, 25 | Oppenheimer | INITIATED | — | Outperform |
| Sep 21, 22 | Maxim Group | DOWNGRADE | Buy | Hold |
| May 13, 22 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Apr 1, 22 | Stephens & Co. | MAINTAINED | — | Overweight |
| Apr 1, 22 | HC Wainwright & Co. | MAINTAINED | — | Buy |
| Feb 10, 22 | HC Wainwright & Co. | MAINTAINED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-15
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-29
Corporate Changes & Voting Matters
8-K · 2026-06-12
Corporate Changes & Voting Matters
8-K · 2026-06-10
Periodic Financial Reports
10-Q · 2026-05-14
Proxy Statements
DEF 14A · 2026-05-11
Corporate Changes & Voting Matters
8-K · 2026-05-06
Headlines
Pulse Biosciences Reaches Enrollment Target in Nanopulse-AF Study
MT Newswires · 7h ago
Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
Business Wire · 8h ago
Pulse Biosciences (PLSE) Stock Fair Value Rises After Analysts Back NsPFA Data
Simply Wall St. · 4d ago
BTIG Initiates Pulse Biosciences at Buy With $70 Price Target
MT Newswires · 14d ago
Pulse Biosciences Completes Enrollment in 100-Patient Thyroid Nodule Study
MT Newswires · 22d ago
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Business Wire · 22d ago
Why Pulse Biosciences Stock Popped Today
Motley Fool · 28d ago
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 33d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.